10,013 Results

Darolutamide + ADT extends metastasis-free survival in non-metastatic castration-resistant prostate cancer. Bayer HealthCare

 Added 1 day ago

Results from the pivotal Phase III ARAMIS trial in patients with non-metastatic castration-resistant prostate cancer (nmCRPC) showed a statistically significant...

Bayer acquires global rights to Vitrakvi and Loxo 195.

 Added 1 day ago

Bayer has exercised its option, under a change-in-control clause in the collaboration agreement with Loxo Oncology, to obtain the exclusive...

Genentech completes sBLA for Kadcyla for adjuvant treatment of HER2-positive early breast cancer (EBC) with residual disease.

 Added 1 day ago

Genentech, a member of the Roche Group announced completing the submission of a supplemental Biologics License Application to the FDA...

FDA postpones PDUFA decision for Duobrii a proposed treatment for psoriasis.- Ortho Dermatologics

 Added 1 day ago

Bausch Health Companies Inc.and its dermatology business, Ortho Dermatologics, one of the largest prescription dermatology health care businesses, announced that...

CE Mark for Ascyrus Medical Dissection Stent-Ascyrus Medical

 Added 2 days ago

Ascyrus Medical, a privately-owned medical device company focused on innovative treatments for aortic dissections, announced the CE mark approval of...

J&J via Ethicon acquires Auris Medical and its robotic technologies

 Added 2 days ago

Johnson & Johnson announced that Ethicon, Inc., entered into a definitive agreement to acquire Auris Health, Inc. for approximately $3.4...

Opdivo + Yervoy success in CheckMate 650 trial for prostate cancer. -BMS

 Added 2 days ago

Bristol-Myers Squibb Company announced data evaluating Opdivo (nivolumab) in combination with Yervoy (ipilimumab) in patients with metastatic castration-resistant prostate cancer...

Keytruda and Lynparza early findings for treatment of prostate cancer.- Merck Inc.

 Added 3 days ago

Merck Inc., announced the presentation of interim data from the Phase 1b/II KEYNOTE-365 umbrella trial investigating Keytruda, Merck’s anti-PD-1 therapy,...

Phase III trials of Rexulti fails to meet primary endpoint in bipolar disorder.- Lundbeck + Otsuka Pharma

 Added 3 days ago

Lundbeck and Otsuka Pharmaceutical announce that data from two global Phase III clinical trials evaluating the safety and efficacy of...

Phase III CAROLINA trial of Tradjenta meets primary endpoint in type 2 diabetes and CV outcomes.- Boehringher + Eli Lilly

 Added 3 days ago

Boehringer and Eli Lilly announced phase III trial CAROLINA met its primary endpoint, defined as non-inferiority for Tradjenta (linagliptin) versus...

Load more